H1N1 vaccines: Key market research findings
- Global plan for influenza vaccines drives market growth
- Intramuscular vaccines segment is the dominant shareholder in the market
- Key vendors – Sanofi, GSK, AstraZeneca, and CSL
Technavio’s market research analysts predict the global H1N1 vaccines market to grow at a CAGR of almost 12% between 2016 and 2020. The global action plan for influenza vaccines is the primary driver for growth in this market. This action plan for influenza vaccines is a comprehensive strategy focused on the increase in the use of seasonal vaccine and vaccine production capacity, and research and development (R&D) for influenza vaccines. World Health Organization (WHO) is attempting to promote the use of influenza vaccines by encouraging its member states to develop a policy for influenza vaccination. In 2015, the Americas dominated the global H1N1 vaccines market, with a market share of around 61%, with the US being the largest revenue contributor. The well-developed healthcare system coupled with better economic conditions is the driving force behind the booming of the market in this region. The growing awareness about vaccination and immunization is expected to propel growth in the H1N1 vaccines market in the Americas during the forecast period.
The new market research report from Technavio presents a breakdown and analysis of the H1N1 vaccines segments based on the route of application (ROA).
“The emergence of a universal influenza vaccine is an upcoming trend in the global H1N1 market. Influenza vaccines are reformulated annually to confer protection against influenza viral strains that are estimated to prevail in the upcoming influenza season. However, these vaccines exhibit inadequate effectiveness against unexpected pandemic viruses and viruses with an antigenic mismatch. As a result, a universal influenza vaccine based on viral protein domains that are conserved across virus subtypes can increase the window for protection against the virus,” says Barath Palada, Lead Analyst, Healthcare & Lifesciences, Technavio Research.
The intramuscular vaccines segment dominated the global H1N1 vaccines market in 2015 by accounting for around 75% of the overall market share. These vaccines are used for treatment in people aged six months or older. Intramuscularly administered H1N1 vaccines comprise of Afluria, Fluarix, Flucelvax, FluLaval, Fluvirin, Fluzone, Fluzone High-Dose, Fluarix Quadrivalent, FluLaval Quadrivalent, Fluzone Quadrivalent, FluBlok, Celvapan, and Focetria.
The key vendors in the market include Sanofi, GSK, AstraZeneca, and CSL. The global H1N1 vaccines market is highly competitive owing to the presence of numerous small and large suppliers. New players are looking to enter the market as the market has tremendous growth opportunities. Vendors are also likely to engage in strategic alliances to market and manufacture drugs.
A more detailed analysis is available in the Technavio report, Global H1N1 Vaccines Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
